News

Eli Lilly jumps deeper into AI with $409M Genetic Leap deal

Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology

Tackling onerousness drug development process through cost-effective genomic analysis platforms

From our blog

Solving the rate-limiting steps of drug discovery

Drug development is arduous and lengthy. That difficulty is reflected in the price of medicine as high drug prices. But the story would be very different and relief brought to all stakeholders if the rate limiting step in the drug discovery process can be solved.

Drugging the RNA: part I, Why do it?

In part I of a series of posts discussing how to drug RNA, we discuss the three dimensions on which a disease target can be drugged, and how RNA’s dual role as both blueprint and object confers it unique properties that make it a particularly attractive target dimension over protein and DNA.

Experimental validation

For AI predictions of complex biological phenomena, experimental validation is the ultimate proof of correctness. But experimental validation is itself subject to myriad factors and considerations that can lead to spurious outcomes if not carefully addressed.